Total
0
Shares
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson - The Market Herald
CEO, Wayne Paterson
Source: Anteris Technologies
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Anteris Technologies (AVR) has finished its proof of concept animal study on conduits treated with its Adapt tissue technology in the carotid artery
  • Conduits treated with the Adapt process showed no evidence of calcification as indicated by histopathology
  • AVR says the results further validate Adapt’s anti-calcification properties in highly problematic areas of surgery
  • The company says the results will push Anteris closer to a viable alternative for patients of coronary by-pass surgery
  • Anteris Technologies last traded at $7.70 on June 14

Anteris Technologies (AVR) proof of concept animal study has shown promising results following testing the variability of conduits treated with its Adapt tissue technology in the carotid artery.

The study used bovine carotid and mesenteric arteries as the conduits, testing the viability of conduits treated with Adapt in the carotid artery in sheep. These conduits ranged from 2.5 millimetres to 3.8 millimetres in diameter, with a six-centimetre length implanted in each animal.

The conduits treated with the Adapt process showed no evidence of calcification as indicated by histopathology.

The study showed no visible signs of inflammation and graphs displayed the presence of a partial neo-intimal layer, which the company says indicates surface remodelling of the vessels.

The company said previous attempts to use animal vessels in the artery had failed due to heavy calcification deposits occurring. However, AVR saw no deposits shown when used with the Adapt treated conduits.

AVR said the global coronary by-pass (CABG) market was estimated at around US4500 million (around A$5833 million) for 2021, with very few viable alternatives for the by-pass graft, other than harvesting a patient’s own saphenous vein.  

Anteris’ Chief Executive Officer, Wayne Paterson said this further validated Adapt’s anti-calcification properties in highly problematic areas on surgery and pushed Anteris closer to a viable alternative for patients of coronary by-pass surgery.

“We are extremely encouraged by these results in a historically difficult setting prone to calcification, associated inflammatory responses and intimal hyperplasia which results in high failure rates,” Anteris’ Vice President and principal investigator Professor Leon Neethling said.

Anteris said following these results, it planned to start a larger animal study in Australia during 2021, where it would implant the conduit into the coronary by-pass position.

Anteris Technologies last traded at $7.70 on June 14.


  

AVR by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) brings ColoSTAT trial to Queensland

" Proteomics International Laboratories (ASX:PIQ) to collaborate for world’s first endometriosis test

Proteomics International Laboratories (PIQ) has penned a research agreement to develop a non-invasive test for endometriosis.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating - The Market Herald

" ResApp Health (ASX:RAP) secures two deals to integrate its diagnostic test

ResApp Health (RAP) has secured two new agreements for its smartphone-based acute respiratory diagnostic test.
Paradigm Biopharmaceuticals (ASX:PAR) - Chairman & CEO, Paul Rennie - The Market Herald

" FDA requests further clarification from Paradigm Biopharmaceuticals (ASX:PAR)

The US Food and Drug Administration has requested further clarification from Paradigm Biopharmaceuticals (PAR) for its Investigational New Drug (IND) application.
Patrys (ASX:PAB) - CEO and Managing Director, Dr James Campbell - The Market Herald

" Patrys’ (ASX:PAB) clinical trials pushed back

Patrys’ (PAB) planned PAT-DX1 clinical trial will be postponed for up to six months due to global manufacturing and supply chain delays.